A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Director Medical Safety and Risk Management

Biology & BiotechConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA$247.1k - $334.3kIn-person

About the Job

Requirements

  • A Medical Degree and a minimum of 3 years of medical practice are required.
  • Sound clinical acumen and a wide range of therapeutic area knowledge are required.
  • Knowledge of clinical research methodology, clinical epidemiology and biostatistics, pharmacovigilance tools and processes, and the relevant regulatory framework is required.
  • Ability to synthesize and analyze safety data from various sources and solve problems in a highly complex environment is required.
  • Strong written and spoken communication skills are required, ideally with demonstrable medical or scientific writing experience.
  • Expertise in international regulations governing drug safety is required.
  • Experience managing compliance or audits is required.
  • Working knowledge of relevant FDA, EU, and ICH guidelines, initiatives, and regulations governing safety reporting and processing for clinical trial environments is highly preferred.
  • Ability to work in a fast-paced environment with rapidly approaching timelines is important.

Responsibilities

  • Lead strategic development of the safety profile of assigned products.
  • Lead active monitoring and continued assessment of safety data through systematic signal detection and critical review of aggregate safety data and literature during all phases of the lifecycle of a defined portfolio of products.
  • Guide clinical development teams regarding all aspects of clinical safety, including trial design, appropriateness of safety endpoints, and analysis and interpretation of safety data.
  • Be accountable for timely completion of all safety deliverables for Clinical Study Reports, preparations for market applications, and other regulatory documents.
  • Lead multidisciplinary teams, such as Safety Risk Management Teams, on safety-relevant topics; escalate relevant safety matters to the appropriate decision-making level with proposals for solutions based on available information.
  • Serve as the safety expert providing strategic input to key stakeholders on product safety; understand product business strategy and the medical context of the product class; and serve as the subject matter expert in relevant safety discussions with regulatory agencies and other significant external bodies.
  • Author and own the content of all safety-relevant documents during clinical development, including DSURs, Development Risk Management Plans, and Safety Analysis Plans, and post-approval, including PSURs, RMPs, medical expert statements, and responses to health authority requests.
  • Own safety-relevant communications such as DHCP letters and company statements.
  • Collaborate with pharmacovigilance and drug safety colleagues from licensing partners to align on a harmonized approach to identifying, evaluating, and communicating safety issues.

Desired Qualifications

  • Pharmaceutical industry experience in pharmacovigilance and/or clinical research or development is preferred.
  • Experience in clinical development is a plus.
  • Excellent networking and relationship-building skills for successful cooperation with internal and external customers.
  • Excellent interpersonal and decision-making skills and strong influencing skills to quickly earn credibility across other functional areas.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs